SomaLogic specializes in high-throughput proteomics technology, primarily through its innovative SomaScan Platform. This platform allows researchers to measure up to 11,000 proteins simultaneously from just a 55-µL sample, significantly enhancing the ability to analyze protein biology and interactions. Utilizing SOMAmer® Reagents—single-stranded DNA aptamers that bind to specific proteins with high sensitivity and specificity—the SomaScan Platform provides a comprehensive analysis of proteomic biomarkers. This technology is designed to facilitate rapid transitions from biomarker discovery to validation across various therapeutic areas, including cardiovascular disease, neurology, and cancer, while maintaining low coefficients of variation (CV) for reproducibility and accuracy.

In addition to the SomaScan Platform, SomaLogic offers SomaSignal Tests, which derive multiple physiological assessments from a single blood sample. These tests leverage the extensive data generated by the SomaScan Assay to provide insights into health states and disease risks, such as cardiovascular health and diabetes. The integration of machine learning models with proteomic data allows for the identification of patterns that correlate with health outcomes, making it a powerful tool for clinical research and potential future diagnostics. Overall, SomaLogic's technologies are positioned to advance the understanding of human health and disease through innovative proteomic solutions.

United States

SomaLogic is a biotechnology company that offers the SomaScan® Platform, the only scalable proteomics platform on the market known for its precision.

SomaLogic

Company Details